Literature DB >> 24338248

Downregulation of T-bet/GATA-3 ratio induced by IL-11 treatment is responsible for Th1/Th2 balance restoration in human immune thrombocytopenic purpura (ITP).

Rongxin Yao1, Ying Lin, Qianqian Li, Xieming Zhou, Xiahui Pan, Yunhua Bao, Muqing He, Baoling Zhu, Wenjian Guo, Xiaoji Lin, Limin Jin.   

Abstract

Abnormal cellular immunity induced by deranged Th1/Th2 profile has been revealed to play a critical role in the pathogenesis of immune thrombocytopenic purpura (ITP). Correction of the shifted Th1/Th2 balance represents a potential therapeutic approach to treat ITP. Here, we investigated the effects of IL-11 on the restoration of Th1/Th2 balance in the peripheral blood mononuclear cells (PBMCs) isolated from adult ITP patients. As shown here, we observed a higher ratio of T-bet/GATA-3 gene expression by quantitative real-time PCR in the PBMCs from ITP patients, consistent with the presence of an abnormally high Th1/Th2 ratio. Remarkably, upon IL-11 treatment, a reversal of T-bet/GATA-3 ratio in ITP was achieved and was shown to be responsible for the restoration of Th1/Th2 balance, with IL-11 at 100 ng/ml demonstrating the highest efficiency. T-bet and GATA-3 are the two transcriptional factors that have been indicated to be the master regulators for Th1 and Th2 lineage commitment, respectively. In the presence of 100 ng/ml IL-11, GATA-3 transcript abundance rose up to ~85-fold of that measured in untreated cells, whereas T-bet transcripts were lowered merely to ~41%, suggesting that GATA-3 was the major contributor for the reversal of T-bet/GATA-3 ratio. Thus, our findings may very well encourage the development of novel medicines that specifically target and correct the T-bet/GATA-3 imbalance identified in ITP.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24338248     DOI: 10.1007/s11239-013-1036-3

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  36 in total

1.  Phase II prospective open-label trial of recombinant interleukin-11 in women with mild von Willebrand disease and refractory menorrhagia.

Authors:  Margaret V Ragni; Rachel C Jankowitz; Kristen Jaworski; Elizabeth P Merricks; Mark T Kloos; Timothy C Nichols
Journal:  Thromb Haemost       Date:  2011-08-11       Impact factor: 5.249

Review 2.  T-bet in disease.

Authors:  Vanja Lazarevic; Laurie H Glimcher
Journal:  Nat Immunol       Date:  2011-06-20       Impact factor: 25.606

Review 3.  Pathogenesis in immune thrombocytopenia: new insights.

Authors:  Jill Johnsen
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2012

Review 4.  Hematopoietic, immunomodulatory and epithelial effects of interleukin-11.

Authors:  U S Schwertschlag; W L Trepicchio; K H Dykstra; J C Keith; K J Turner; A J Dorner
Journal:  Leukemia       Date:  1999-09       Impact factor: 11.528

5.  Transcription factor GATA-3 is differentially expressed in murine Th1 and Th2 cells and controls Th2-specific expression of the interleukin-5 gene.

Authors:  D H Zhang; L Cohn; P Ray; K Bottomly; A Ray
Journal:  J Biol Chem       Date:  1997-08-22       Impact factor: 5.157

6.  T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura.

Authors:  Bob Olsson; Per-Ola Andersson; Margareta Jernås; Stefan Jacobsson; Björn Carlsson; Lena M S Carlsson; Hans Wadenvik
Journal:  Nat Med       Date:  2003-08-24       Impact factor: 53.440

Review 7.  The pathogenesis of chronic immune thrombocytopenic purpura.

Authors:  Robert McMillan
Journal:  Semin Hematol       Date:  2007-10       Impact factor: 3.851

8.  IL-11 regulates autoimmune demyelination.

Authors:  Blake T Gurfein; Yueting Zhang; Carolina B López; Azeb Tadesse Argaw; Andleeb Zameer; Thomas M Moran; Gareth R John
Journal:  J Immunol       Date:  2009-09-04       Impact factor: 5.422

9.  An instructive component in T helper cell type 2 (Th2) development mediated by GATA-3.

Authors:  J D Farrar; W Ouyang; M Löhning; M Assenmacher; A Radbruch; O Kanagawa; K M Murphy
Journal:  J Exp Med       Date:  2001-03-05       Impact factor: 14.307

10.  Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis.

Authors:  L Moreland; R Gugliotti; K King; W Chase; M Weisman; T Greco; R Fife; J Korn; R Simms; J Tesser; J Hillson; J Caldwell; T Schnitzer; D Lyons; U Schwertschlag
Journal:  Arthritis Res       Date:  2001-04-10
View more
  5 in total

1.  Analysis of clinical effects and mechanism of recombinant human interleukin-11 with glucocorticoids for treatment of idiopathic thrombocytopenic purpura.

Authors:  Xifeng Wu; Lijuan Wang; Lin Sun; Tantan Li; Xuehong Ran
Journal:  Exp Ther Med       Date:  2016-12-21       Impact factor: 2.447

2.  Clinical efficacy of Yingliu mixture combined with metimazole for treating diffuse goitre with hyperthyroidism and its impact on related cytokines.

Authors:  Hua Yang; Yilei Cong; Tengfei Wu; Hong Tang; Muhao Ma; Juanhua Zeng; Wenya Zhang; Zhen Lian; Xinyu Yang
Journal:  Pharm Biol       Date:  2017-12       Impact factor: 3.503

3.  Integrated Network Pharmacology and Metabolomics Analysis of the Therapeutic Effects of Zi Dian Fang on Immune Thrombocytopenic Purpura.

Authors:  Yubo Li; Yamei Li; Wenliang Lu; Hongbin Li; Yuming Wang; Houmin Luo; Yuanyuan Wu; Wenying Dong; Gang Bai; Yanjun Zhang
Journal:  Front Pharmacol       Date:  2018-06-19       Impact factor: 5.810

4.  Thrombocytopenia in solid tumors: Prognostic significance.

Authors:  Majid Ghanavat; Mina Ebrahimi; Hassan Rafieemehr; Mahmood Maniati; Masumeh Maleki Behzad; Saeid Shahrabi
Journal:  Oncol Rev       Date:  2019-05-14

5.  High-Dose Dexamethasone Alters the Increase in Interleukin-16 Level in Adult Immune Thrombocytopenia.

Authors:  Xinru Wang; Lizhen Li; Yuanjian Wang; Xin Li; Qi Feng; Yu Hou; Chunhong Ma; Chengjiang Gao; Ming Hou; Jun Peng
Journal:  Front Immunol       Date:  2019-03-18       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.